The Global Virtual Symposium on Liquid Biopsy 2026 is now underway, bringing together internationally recognised scientists, clinicians, innovators, and industry leaders to explore the latest advances in liquid biopsy and its rapidly expanding role in precision oncology.
🔴 Now Speaking: Prof. Klaus Pantel, MD
Professor, University Medical Center Hamburg-Eppendorf (UKE), Germany
Presentation: Liquid Biopsy 2026: State-of-the-Art
As one of the pioneers of the liquid biopsy field, Prof. Klaus Pantel has played a defining role in transforming cancer diagnostics through his groundbreaking work on circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA). His research has helped establish liquid biopsy as a cornerstone of modern precision medicine, enabling clinicians to monitor cancer through minimally invasive blood-based testing.
In this plenary lecture, Prof. Pantel presents a comprehensive overview of the current state of liquid biopsy, highlighting recent scientific breakthroughs, emerging technologies, and the growing clinical impact of this rapidly evolving field. The session explores how liquid biopsy is reshaping cancer care through:
• Earlier cancer detection
• Minimal residual disease (MRD) assessment
• Real-time treatment monitoring
• Detection of therapy resistance
• Personalised treatment selection using molecular biomarkers
His presentation also provides valuable insights into the challenges and future opportunities for integrating liquid biopsy into routine clinical practice, bringing us closer to more precise, patient-centred cancer care.
We extend our sincere appreciation to Prof. Klaus Pantel for sharing his expertise and to the global scientific community participating in today’s symposium. Your contributions continue to drive innovation, collaboration, and progress in precision oncology.
This conference is organized by Impact Research Communications (IRC)
More info: https://liquidbio.ircconferences.net/ | Advances in Liquid Biopsy
